Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.42 |
| ▸ | TACR1 | P25103 | 8/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.39 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5493242 | 0.69 | CXCR4 (0.50) | HRH3CHRM1 | |
| SCHEMBL5493369 | 0.69 | CXCR4 (0.50) | HRH3CHRM1 | |
| SCHEMBL5495347 | 0.69 | CXCR4 (0.50) | HRH3CHRM1 | |
| SCHEMBL4937801 | 0.67 | L3MBTL3 (0.50) | L3MBTL3MBTD1L3MBTL1TP53BP1HRH3 | |
| SCHEMBL4938449 | 0.66 | HTR2C (0.43) | TACR1CHRM1 | |
| SCHEMBL5488053 | 0.63 | CXCR4 (0.46) | HRH3CHRM1 | |
| SCHEMBL5487372 | 0.63 | HRH3 (0.48) | HRH3CHRM1 | |
| SCHEMBL4941263 | 0.63 | CXCR4 (0.46) | HRH3CHRM1 | |
| SCHEMBL5491004 | 0.63 | CXCR4 (0.46) | HRH3CHRM1 | |
| Hydrochloric Acid SCHEMBL3716147 | 0.63 | CHRM1 (0.60) | L3MBTL1CHRM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279491-B2 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-09 | — | — | US | claimed |
| EP-1556046-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2005-07-27 | — | — | EP | claimed |
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-06 | — | — | US | claimed |
| WO-2004037257-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | claimed |
| US-7279491-B2 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-09 | — | — | US | disclosed |
| EP-1556046-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2005-07-27 | — | — | EP | disclosed |
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-06 | — | — | US | disclosed |
| WO-2004037257-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | HRH2, HNMT, HRH3 | L3MBTL3 4833/4885MBTD1 3982/4885TACR1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.